

## **TECHNICAL DATA SHEET**

CyFlow™ CD97 Purified Anti-Hu; Clone MEM-180



AH423849

# For Research Use Only. Not for use in diagnostic or therapeutic procedures.

### **Specifications**

Antigen	CD97
Alternative Names	EMR1
Clone	MEM-180
Clonality	monoclonal
Format	Purified
Host / Isotype	Mouse / IgG1
Species Reactivity	Human
Negative Species Reactivity	_
Quantity [Concentration]	0.1 mg [ 1 mg/ml ]
Immunogen	PHA-activated peripheral blood cells

## **Specificity**

The mouse monoclonal antibody MEM-180 recognizes an unique epitope on CD97 antigen, a 75-85 kDa surface glycoprotein of G-protein-coupled receptor family, expressed on activated B and T lymphocytes, monocytes/macrophages, dendritic cells and granulocytes.

#### **Contact Information:**

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: <u>info@sysmex-partec.com</u>

Rev 1.0 Date: 2016-07-15 EN CyFlow™ CD97 Purified



## **Application**

Based on published sources, this antibody is suitable for the following applications:

- Flow cytometry
- · Immunoprecipitation

#### Storage Buffer

The reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.1% (w/v) sodium azide.

## Storage and Stability

Storage	Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
Stability	Do not use after expiration date stamped on vial label.

#### **Background Information**

CD97 is a G-protein-coupled seven-span transmembrane adhesive receptor that is constitutively expressed on granulocytes and monocytes and rapidly upregulated on T and B cells upon activation. CD97 is produced in alternatively spliced forms and its cellular ligand is CD55 (DAF), which protects various cell types from complement-mediated damage. Interaction of CD97 on leukocytes and CD55 on vessel cells probably facilitate leukocyte activation and migration into the tissues, similarly, CD97 seems to play a role in tumor migration and invasiveness. CD97 is involved in T cell regulation and peripheral granulocyte homeostasis.

#### References

- Kishimoto T, Goyert S, Kikutani H, Mason D, Miyasaka M, Moretta L, Ohno T, Okumura K, Shaw S, Springer TA, Sugamura K, Sugawara H, von dem Borne AEGK, Zola H (Eds): Leucocyte Typing VI. Garland Publishing Inc, New York. 1997; 1-1342. < NLM ID: 9712219 >
- Visser L, de Vos AF, Hamann J, Melief MJ, van Meurs M, van Lier RA, Laman JD, Hintzen RQ: Expression of the EGF-TM7 receptor CD97 and its ligand CD55 (DAF) in multiple sclerosis. J Neuroimmunol. 2002 Nov; 132(1-2):156-63. < PMID: 12417446 >
- Wobus M, Vogel B, Schmücking E, Hamann J, Aust G: N-glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding.
   Int J Cancer. 2004 Dec 10; 112(5):815-22. < PMID: 15386373 >

#### **Contact Information:**

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com

Rev 1.0 Date: 2016-07-15 EN CyFlow™ CD97 Purified



- Galle J, Sittig D, Hanisch I, Wobus M, Wandel E, Loeffler M, Aust G: Individual cell-based models of tumor-environment interactions: Multiple effects of CD97 on tumor invasion. Am J Pathol. 2006 Nov; 169(5):1802-11. < PMID: 17071601 >
- Wang T, Tian L, Haino M, Gao JL, Lake R, Ward Y, Wang H, Siebenlist U, Murphy PM, Kelly K: Improved antibacterial host defense and altered peripheral granulocyte homeostasis in mice lacking the adhesion class G protein receptor CD97. Infect Immun. 2007 Mar; 75(3):1144-53.
   < PMID: 17158902 >
- Abbott RJ, Spendlove I, Roversi P, Fitzgibbon H, Knott V, Teriete P, McDonnell JM, Handford PA, Lea SM: Structural and functional characterization of a novel T cell receptor co-regulatory protein complex, CD97-CD55. J Biol Chem. 2007 Jul 27; 282(30):22023-32. < PMID: 17449467 >

The Safety Data Sheet for this product is available at www.sysmex-partec.com/services.	
--	--

#### **Contact Information:**

Rev 1.0 Date: 2016-07-15 EN CyFlow™ CD97 Purified